Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors - Wikidata - awgldk - TriplyDB

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

http://www.wikidata.org/entity/Q34129269

about

The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.

P2860

Q26751155-683C4E00-48E9-421B-BDBB-9751D19121B6 Q27011840-0AF57967-E7EC-46E4-8B40-3A3EE25ECFCF Q36480124-A0D886D7-1A7C-4C40-AC12-DB897729F02B Q36998239-563C7A6A-D2B3-418C-ACA4-4460647AD245 Q37725493-2237241D-4734-4A9F-928E-A59B88506F78

P2860

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

http://www.wikidata.org/entity/Q34129269

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@ast

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@en

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@nl

type

label

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@ast

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@en

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@nl

prefLabel

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@ast

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@en

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@nl

P1433

Q34129269-F2C0D4DC-DABD-4FF6-83BE-28B8B06B2E2C

P1476

Q34129269-F39F9628-24A5-4DC9-9872-D577951FE998

P2093

Q34129269-7F22CB6E-68F9-4CFD-9533-2D31146D95D8

Q34129269-83898405-FD4D-49C2-9243-46E5F2B02CE8

Q34129269-9E51D8E5-9599-4B3F-B90B-47C851A41904

Q34129269-D44B85C7-6B23-4342-A5DB-AAC84D736D6B

P2860

Q34129269-07BD2A9A-1464-428D-BCF0-FD836893E136

Q34129269-19774A2D-992A-481D-AC73-13656C5C996F

Q34129269-2143AB46-5D23-44E9-9B19-9C0B05505829

Q34129269-3409F153-FB43-468B-9169-3F8D597B46E6

Q34129269-37071FB4-9461-4881-8651-66EB222982F0

Q34129269-41DF9172-AA87-4D7E-9A93-2490149EFB35

Q34129269-4D3FF4CE-33E0-4AA5-842A-A30DB87B2575

Q34129269-4F3957BB-A4B6-448B-BD44-6DF4952E1441

Q34129269-5CD65851-AE7B-4E17-A0AE-3E9D1FE0217C

Q34129269-6B366F6C-39AC-43EF-A4C8-09B03180444E

P304

Q34129269-293A55FE-15B8-47E2-9DDF-3A662F92735D

P31

Q34129269-220373DF-9A66-4400-88D3-AC2B70F806C1

P356

Q34129269-96EDAD2B-4D28-430A-BC38-2FE6C8C26CE0

P433

Q34129269-15B2958B-7B8F-4CB9-A8E1-6EF3B2B44387

P478

Q34129269-F27C1503-322B-428A-BB80-6D320E735181

P50

Q34129269-0239C3A9-366C-47EB-9938-E81DB0ECAE37

P577

Q34129269-8D98FB41-423A-4FEF-B214-8DD966647DF9

P698

Q34129269-1C958BD3-47C4-4117-8ADB-2704B9E48198

P932

Q34129269-DCE89C5C-B4B7-420F-9583-A05C730FE19C

P356

CAD.0B013E3283618B7B

P1433

Anti-Cancer Drugs

P1476

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

@en

P2093

Courtney Eddings

http://www.w3.org/2001/XMLSchema#string

Mrinal P Dutia

http://www.w3.org/2001/XMLSchema#string

Primo N Lara

http://www.w3.org/2001/XMLSchema#string

Scott Christensen

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

P304

636-640

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CAD.0B013E3283618B7B

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Thomas J Semrad

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23698253

http://www.w3.org/2001/XMLSchema#string

P932

4153755

http://www.w3.org/2001/XMLSchema#string